AMRS Stock Overview
About the company
Amyris, Inc. operates as a biotechnology company in Europe, North America, Asia, South America, and internationally. It creates, manufactures, and commercializes consumer products and ingredient, including clean beauty, personal care, and health and wellness consumer products; and ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. The company markets its products under the Biossance, JVN, Rose Inc., Pipette, Costa Brazil, OLIKA, Purecane, Terasana, MenoLabs, EcoFabulous, Stripes, and 4U by Tia brand names. It has a collaboration and license agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.
Snowflake Analysis
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Amyris, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.45 |
| 52 Week High | US$5.15 |
| 52 Week Low | US$0.99 |
| Beta | 1.1 |
| 1 Month Change | 5.07% |
| 3 Month Change | -25.26% |
| 1 Year Change | -66.67% |
| 3 Year Change | -33.79% |
| 5 Year Change | -78.33% |
| Change since IPO | -99.41% |
Recent News & Updates
Recent updates
Does This Valuation Of Amyris, Inc. (NASDAQ:AMRS) Imply Investors Are Overpaying?
Mar 22
At US$2.95, Is Amyris, Inc. (NASDAQ:AMRS) Worth Looking At Closely?
Oct 31Amyris Cost Breakdown
Oct 07Recurring Marketing Exclusivity Deals Accelerate Amyris On Path To Profitability
Oct 01Are Investors Undervaluing Amyris, Inc. (NASDAQ:AMRS) By 43%?
Sep 02Amyris: In Dire Need For Additional Capital
Aug 22Amyris, Inc. (NASDAQ:AMRS) Just Reported, And Analysts Assigned A US$10.91 Price Target
Aug 12Amyris' Vertically-Integrated Business Model Transitioning From Investment Mode To Payoff Mode
Aug 08Amyris: Revenues Need To Catch Expenses
Jul 08Amyris: Elevated Cash Usage Causes Investors To Head For The Exits
May 11Amryis Update: Building Value One Brick At A Time
Apr 28Amyris: JVN Could Be Their Most Valuable Brand Yet
Mar 19Amyris: Surviving The Perfect Storm
Feb 03Amyris: MenoLabs Acquisition Extends The Platform Into New Markets
Jan 28Amyris: Success With RebM Will Indicate A Manufacturing Advantage
Jan 19Amyris: Enabling Environmentally Sustainable Beauty Products
Jan 03Amyris: Well Positioned In The Cannabinoids Market
Dec 17Amyris: Vaccine Upside
Nov 30Amyris Buying Opportunity Created By Q3 Miss, Mega Convert And Potential Revolutionary COVID Vaccine
Nov 19Amyris: Assessing Financial Capacity To Sustain Organic Growth, Carry COVID Research And Pay For Acquisition
Nov 04Amyris: Cash Burn Accelerates As The Facade Is Cracking
Aug 16Amyris Stock Forecast For 2021: Where Is It Headed?
Jul 28Amyris: How Lead In Synthetic Biology Could Brew Up Big Profits
Jun 28Finding Value In Beauty And Wellness Through Amyris
Jun 06Amyris EPS beats by $0.52, beats on revenue
May 06Amyris And Ingredion enter $100M partnership
May 03Amyris’ acne formulation shows superior efficacy in early clinical study
Feb 02Amyris Is Setting Up For A Monster Run
Dec 17Amyris: Management Now Eyeing Asset Sales To Raise Much-Needed Additional Capital
Nov 09Amyris, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 06Shareholder Returns
| AMRS | US Chemicals | US Market | |
|---|---|---|---|
| 7D | 9.8% | -1.0% | -0.3% |
| 1Y | -66.7% | -10.2% | -14.8% |
Return vs Industry: AMRS underperformed the US Chemicals industry which returned -8.3% over the past year.
Return vs Market: AMRS underperformed the US Market which returned -14.2% over the past year.
Price Volatility
| AMRS volatility | |
|---|---|
| AMRS Average Weekly Movement | 11.8% |
| Chemicals Industry Average Movement | 5.2% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AMRS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: AMRS's weekly volatility has decreased from 19% to 12% over the past year, but is still higher than 75% of US stocks.
Amyris, Inc. Fundamentals Summary
| AMRS fundamental statistics | |
|---|---|
| Market Cap | US$531.06m |
| Earnings (TTM) | -US$528.51m |
| Revenue (TTM) | US$269.85m |
2.0x
P/S Ratio-1.0x
P/E RatioIs AMRS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMRS income statement (TTM) | |
|---|---|
| Revenue | US$269.85m |
| Cost of Revenue | US$367.58m |
| Gross Profit | -US$97.74m |
| Other Expenses | US$430.77m |
| Earnings | -US$528.51m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.44 |
| Gross Margin | -36.22% |
| Net Profit Margin | -195.86% |
| Debt/Equity Ratio | -188.9% |
How did AMRS perform over the long term?
See historical performance and comparison